Covid-19: Where are we on immunity and vaccines?-Reference-Cited by-同舟云学术

Covid-19: Where are we on immunity and vaccines?

Published:2020-08-05 Issue: Volume: Page:m3096
ISSN:1756-1833
Container-title:BMJ
language:en
Short-container-title:BMJ

Author:

Mahase Elisabeth

Publisher

BMJ

Subject

General Engineering

Reference7 articles.

1. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

2. Covid-19: Oxford team begins vaccine trials in Brazil and South Africa to determine efficacy

3. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

4. CanSino Biologics. Recombinant novel coronavirus vaccine (adenovirus type 5 vector) received military specially-needed drug approval. 29 Jun 2020. https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0629/2020062900123.pdf.

5. Kramer AE. Russia sets mass vaccination for October after shortened trial. New York Times 2020 Aug 2. https://www.nytimes.com/2020/08/02/world/europe/russia-trials-vaccine-October.html.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine development: Current trends and technologies;Life Sciences;2024-01

2. Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2022-04

3. Learning from the past and present: social science implications for COVID-19 immunity-based documentation;Humanities and Social Sciences Communications;2021-09-27

4. Advances in gene-based vaccine platforms to address the COVID-19 pandemic;Advanced Drug Delivery Reviews;2021-03

5. Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic;JMIR Public Health and Surveillance;2021-02-26